Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$0.7400
Last update: Dec 16, 9:01 AM
Comments
Loading...
Barinthus Biotherapeutics Analyst Ratings and Price Targets | NASDAQ:BRNS | Benzinga
Barinthus Biotherapeutics PLC has a consensus price target of $5.5 based on the ratings of 3 analysts. The high is $9.5 issued by Alliance Global Partners on August 13, 2024. The low is $3 issued by Barclays on June 13, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on November 17, 2025, March 21, 2025, and January 13, 2025, respectively. With an average price target of $3.33 between HC Wainwright & Co., there's an implied 350.45% upside for Barinthus Biotherapeutics PLC from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Alliance Global Partners
Barclays
1calculated from analyst ratings
Analyst Ratings for Barinthus Biotherapeutics
FAQ
What is the target price for Barinthus Biotherapeutics (BRNS) stock?
The latest price target for Barinthus Biotherapeutics (NASDAQ:BRNS) was reported by HC Wainwright & Co. on November 17, 2025. The analyst firm set a price target for $4.00 expecting BRNS to rise to within 12 months (a possible 440.54% upside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Barinthus Biotherapeutics (BRNS)?
The latest analyst rating for Barinthus Biotherapeutics (NASDAQ:BRNS) was provided by HC Wainwright & Co., and Barinthus Biotherapeutics maintained their buy rating.
When was the last upgrade for Barinthus Biotherapeutics (BRNS)?
There is no last upgrade for Barinthus Biotherapeutics
When was the last downgrade for Barinthus Biotherapeutics (BRNS)?
There is no last downgrade for Barinthus Biotherapeutics.
When is the next analyst rating going to be posted or updated for Barinthus Biotherapeutics (BRNS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Barinthus Biotherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Barinthus Biotherapeutics was filed on November 17, 2025 so you should expect the next rating to be made available sometime around November 17, 2026.
Is the Analyst Rating Barinthus Biotherapeutics (BRNS) correct?
While ratings are subjective and will change, the latest Barinthus Biotherapeutics (BRNS) rating was a maintained with a price target of $3.00 to $4.00. The current price Barinthus Biotherapeutics (BRNS) is trading at is $0.74, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
